Table of Contents Author Guidelines Submit a Manuscript
Journal of Chemistry
Volume 2013 (2013), Article ID 412353, 10 pages
http://dx.doi.org/10.1155/2013/412353
Research Article

Development and Validation of a Specific Stability Indicating High Performance Liquid Chromatographic Methods for Related Compounds and Assay of Solifenacin Succinate

1Department of Chemistry, Acharya Nagarjuna University, Nagarjunanagar, Guntur 522210, Andhra Pradesh, India
2Hetero Drugs Limited, Balanagar, Hyderabad 500018, Andhra Pradesh, India

Received 12 June 2012; Accepted 18 October 2012

Academic Editor: Ahmet Kilic

Copyright © 2013 B. V. Rami Reddy et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. J. Wein, “Pharmacological agents for the treatment of urinary incontinence due to overactive bladder,” Expert Opinion on Investigational Drugs, vol. 10, no. 1, pp. 65–83, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. K. Ikeda, S. Kobayashi, M. Suzuki et al., “M3 receptor antagonism by the novel antimuscarinic agent solifenacin in the urinary bladder and salivary gland,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 366, no. 2, pp. 97–103, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. M. C. Michel, M. Oelke, and N. Zinner, “Novel muscarinic antagonists to treat incontinence and/or overactive bladder,” Drug Discovery Today, vol. 2, no. 1, pp. 1–6, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. H. N. Mistri, A. G. Jangid, A. Pudage, D. M. Rathod, and P. S. Shrivastav, “Highly sensitive and rapid LC-ESI-MS/MS method for the simultaneous quantification of uroselective α1-blocker, alfuzosin and an antimuscarinic agent, solifenacin in human plasma,” Journal of Chromatography B, vol. 876, no. 2, pp. 236–244, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Macek, P. Ptáček, and J. Klíma, “Determination of solifenacin in human plasma by liquid chromatography-tandem mass spectrometry,” Journal of Chromatography B, vol. 878, no. 31, pp. 3327–3330, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. T. Yanagihara, T. Aoki, Y. Soeishi, T. Iwatsubo, and H. Kamimura, “Determination of solifenacin succinate, a novel muscarinic receptor antagonist, and its major metabolite in rat plasma by semi-micro high performance liquid chromatography,” Journal of Chromatography B, vol. 859, no. 2, pp. 241–245, 2007. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Radha Krishna, B. M. Rao, and N. Someswara Rao, “A validated rapid stability-indicating method for the determination of related substances in Solifenacin Succinate by ultra-fast liquid chromatography,” Journal of Chromatographic Science, vol. 48, no. 10, pp. 807–810, 2010. View at Google Scholar · View at Scopus
  8. B. S. Landge, A. S. Jadhav, B. S. Dahale et al., “Development and validation of new chromatographic method for the determination of enantiomeric and diastereomeric purity of solifenacin succinate: an anti-muscarinic agent,” Chromatography Research International, vol. 2011, Article ID 243491, 7 pages, 2011. View at Publisher · View at Google Scholar
  9. D. Desai, G. Patel, N. Shukla, and S. Rajput, “Development and validation of stability-indicating HPLC method for solifenacin succinate: isolation and identification of major base degradation product,” Acta Chromatographica, vol. 24, no. 3, pp. 399–418, 2012. View at Google Scholar
  10. N. Desai, S. S. Hussen, S. G. Vasanthraju, A. Karthik, and N. Udupa, “Development & validation of stability indicating HPLC method for determination of Solifenacin in bulk formulations,” International Journal of Pharmacy and Pharmaceutical Sciences, vol. 3, no. 1, pp. 70–74, 2011. View at Google Scholar · View at Scopus
  11. L. Singh and S. Nanda, “Spectrophotometric estimation of solifenacin succinate in tablet formulations,” Pharmaceutical Methods, vol. 2, no. 1, pp. 21–24, 2011. View at Google Scholar
  12. R. Seetharaman, K. S. Lakshmi, D. K. Boggavarappu, G. Hariprasad, and K. R. Ravi, “Determination of Balofloxacin in pharmaceutical formulation by zero, first and second order derivative spectrophotometric methods,” International Journal of Research in Pharmaceutical Sciences, vol. 2, no. 3, pp. 1052–1057, 2011. View at Google Scholar · View at Scopus
  13. J. D. Desai, G. Patel, D. Ruikar, A. R. Jain, and J. S. Rajput, “Development and validation of stability-indicating HPTLC method of solifenacin succinate,” Asian Journal of Pharmaceutical and Biological Research, vol. 1, no. 3, pp. 310–316, 2011. View at Google Scholar
  14. ICH Guideline Q3A(R2), impurities in New Drug Substances, 2006.
  15. ICH Guideline Q7A, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients, 2005.
  16. ICH Q2(R1) Validation of Analytical Procedures, Text and Methodology, 2005.
  17. ICH Q1A(R2), “Stability testing of new drug substances and products,” in International Conference on Harmonization, 2003.
  18. ICH, “Stability testing of new drugs substances and products (Q1AR),” in International Conference on Harmonization (IFPMA '00), Geneva, Switzerland, 2000.
  19. “ICH draft guidelines on validation of analytical procedures: definitions and terminology, federal Register,” in International Conference on Harmonization (IFPMA '95), p. 11260, Geneva, Switzerland, 1995.